Damian Marron
Vermogen: 13 982 $ op 30-06-2026
Vermogen: 13 982 $ op 30-06-2026
Damian Marron is currently Chairman at Circio Holding ASA since 2020, Non-Executive Chairman at Cytoseek Ltd., Chairman at Indegra Therapeutics Ltd., Chairman at Onya Therapeutics Ltd., Chairman at Nicox SA since 2024, Director at Cantargia AB since 2021, Director at Loxbridge Research LLP, Director at Agalimmune Ltd., Director at Resolys Bio, Inc. since 2018, and Head-Biopharma at Treehill Partners, LLC.
Former roles include Chief Executive Officer at Cytheris SA, Chief Executive Officer at Trophos SA from 2008 to 2012, Chief Executive Officer & Director at Sangamo Therapeutics France SAS from 2013 to 2015, Chairman at PepGen Ltd., Non-Executive Chairman at Imophoron Ltd., Director at France Biotech Association, Independent Non-Executive Director at Bone Therapeutics SA, Director at Theralpha, Executive Vice President-Corporate Development at Nicox SA from 2002 to 2008, Manager-Drug Group at Orphan Europe SARL, Head-European Development Business at Bausch & Lomb (Australia) Pty Ltd. in 2013, Principal at Rhone-Poulenc Rorer BV from 1991 to 2013, and Principal at Glaxo Wellcome Immobilière de Recherche SA from 1986 to 2013.
Education includes an undergraduate degree from The University of Liverpool, conferred in 1985.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
CANTARGIA AB 0,03% | 31-12-2024 | 63.054 ( 0,03% ) | 13 982 $ | 30-06-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| CIRCIO HOLDING ASA | Voorzitter | 29-04-2020 |
| CANTARGIA AB | Directeur/Bestuurslid | 26-05-2021 |
| NICOX SA | Voorzitter | 16-07-2024 |
Agalimmune Ltd.
Agalimmune Ltd. Pharmaceuticals: MajorHealth Technology Develops anti-cancer immunotherapy technology | Directeur/Bestuurslid | - |
Cytoseek Ltd.
Cytoseek Ltd. Miscellaneous Commercial ServicesCommercial Services Research and develops synthetic artificial membrane proteins | Voorzitter | - |
Treehill Partners, LLC | Corporate Officer/Principal | - |
Resolys Bio, Inc.
Resolys Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Operates biotechnology company focusing on therapeutic agents for chronic disorders | Directeur/Bestuurslid | 01-03-2018 |
Loxbridge Research LLP
Loxbridge Research LLP Financial ConglomeratesFinance Operates as an investment and project-management company | Directeur/Bestuurslid | - |
| Bedrijven | Functie | Einde |
|---|---|---|
| TXCELL | Algemeen Directeur | 28-04-2015 |
| ░░░░░░░ ░░ | ░░░░░░░░ ░░░░░░░░░ | - |
| ░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░ ░░░░ ░░░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 21 |
|---|---|
Nicox SA
Nicox SA Pharmaceuticals: MajorHealth Technology Manufactures and sells ophthalmology biopharmaceuticals | Health Technology |
The University of Liverpool
The University of Liverpool Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cytheris SA
Cytheris SA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for immune modulation | Health Technology |
Trophos SA
Trophos SA Pharmaceuticals: MajorHealth Technology Develops drugs for the prevention of neuronal loss for neurodegenerative diseases | Health Technology |
France Biotech Association
France Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates an organisation for growth of health industry | Commercial Services |
Orphan Europe SARL
Orphan Europe SARL Pharmaceuticals: MajorHealth Technology Develops and distributes orphan drugs for the treatment of rare diseases and metabolic disorders | Health Technology |
Bausch & Lomb (Australia) Pty Ltd.
Bausch & Lomb (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and distributes prescription medicines | Health Technology |
Sangamo Therapeutics France SAS
Sangamo Therapeutics France SAS BiotechnologyHealth Technology Develops cellular immunotherapy platforms that treats severe inflammatory and autoimmune diseases | Health Technology |
Rhone-Poulenc Rorer BV | |
Glaxo Wellcome Immobilière de Recherche SA
Glaxo Wellcome Immobilière de Recherche SA Real Estate DevelopmentFinance Provides real estate services | Finance |
Cantargia AB
Cantargia AB Pharmaceuticals: MajorHealth Technology Creates and develops antibody therapeutics for the treatment of leukemia | Health Technology |
Bone Therapeutics SA
Bone Therapeutics SA Pharmaceuticals: MajorHealth Technology Develops regenerative therapy products for addressing unmet medical needs in the field of bone diseases and orthopedics | Health Technology |
Circio Holding ASA
Circio Holding ASA BiotechnologyHealth Technology Develops active immunotherapy cancer vaccines | Health Technology |
Theralpha | |
Loxbridge Research LLP
Loxbridge Research LLP Financial ConglomeratesFinance Operates as an investment and project-management company | Finance |
Agalimmune Ltd.
Agalimmune Ltd. Pharmaceuticals: MajorHealth Technology Develops anti-cancer immunotherapy technology | Health Technology |
Resolys Bio, Inc.
Resolys Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Operates biotechnology company focusing on therapeutic agents for chronic disorders | Commercial Services |
Cytoseek Ltd.
Cytoseek Ltd. Miscellaneous Commercial ServicesCommercial Services Research and develops synthetic artificial membrane proteins | Commercial Services |
Pepgen Ltd.
Pepgen Ltd. Packaged SoftwareTechnology Services Develops peptide drug delivery platform technology | Technology Services |
Treehill Partners, LLC | |
Imophoron Ltd.
Imophoron Ltd. BiotechnologyHealth Technology Develops a novel vaccine platform for use on emerging infectious diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau